A functional screen of RNA binding proteins identifies genes that promote or limit the accumulation of CD138+ plasma cells.

Increasing the scale of IVT presents several challenges, but optimized protocols and comprehensive characterization can lead to a successful mRNA therapeutic.

Lap-in-the-loop platforms like eCOMPASS can help you de-risk potential setbacks in your RNA therapeutic development.

Eclipsebio is proud to sponsor the 2026 RNA Delivery Prato meeting to discuss recent discoveries and challenges in RNA delivery.

Eclipsebio's eSENSE Break uses sequencing-based analytics to map RNA fragmentation and circular RNA nicking sites at single-nucleotide resolution.